Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

This study is testing whether adding Immuncell-LC (an immune cell therapy made from the patient's own activated T-cells) to the standard chemotherapy drug gemcitabine improves survival after surgery for pancreatic cancer. **You may be eligible if...** - You are between 20 and 80 years old - You have been diagnosed with pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) and have had it fully or mostly removed by surgery (R0 or R1 resection) at least 2 weeks ago but no more than 12 weeks ago - There is no evidence the cancer has spread to other organs - You are scheduled to receive gemcitabine chemotherapy after surgery - Your general health is adequate (ECOG 0–2) and major organs are functioning well **You may NOT be eligible if...** - You have evidence of distant spread (metastases) - You had a non-curative surgery - Your organ function is too poor - You have had prior chemotherapy or radiation for this cancer Talk to your doctor to see if this trial is right for you.